Drug Delivery Business

Chris Newmarker

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Dexcom adds former Stryker CFO to board

By

CGM maker Dexcom (Nasdaq: DXCM) is adding the former CFO of orthopedic and surgical device giant Stryker to its board of directors. Glenn Boehnlein’s appointment was in effect yesterday — the day of the announcement. Boehnlein’s addition expands the size of Dexcom’s board to 13. Boehnlein retired from Stryker last year after 22 years with […]

MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance

By

MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. […]

Abbott wins FDA authorization for dual glucose-ketone sensor

By

Abbott (NYSE:ABT) announced today that the FDA has authorized its dual glucose-ketone sensing technology for people with diabetes. The authorization of the Libre Duo 10 Day system — which provides 10 days of wear time — comes three months after the company reported a CE mark in the EU for the Libre Duo and Libre […]

Senseonics sees activist investor take a major stake

By

Activist investor Sessa Capital has taken a sizeable stake in long-term, implantable CGM company Senseonics (NYSE: SENS), according to an SEC Schedule 13G filed today. The SEC filing lists Sessa directly owning 4,437,532 shares of Senseonics common stock, with warrants to buy another 8,000,000 shares of stock subject to a 9.9% blocker provision that prevents investors from […]

Abbott, Google to deliver glucose insights through artificial intelligence

By

Abbott (NYSE: ABT) is turning to Google’s artificial intelligence expertise to leverage more glucose insights for users of the Abbott Park, Illinois–based life science giant’s Lingo biowearable. Under a multiyear agreement announced today, ongoing glucose insights from Abbott’s Lingo biowearable will combine with Google Health’s technology to provide a more comprehensive view of people’s health. […]

Senseonics more than doubles Q2 revenue in post-Ascensia era

By

Senseonics  (NYSE:SENS) stock is up more than 26% today after it reported what CEO Tim Goodnow described as the strongest quarter in the implantable, long-term CGM company’s history. BTIG analysts Marie Thibault, Alexandra Pang, and Sam Eiber noted that the European commercial transition from Ascensia Diabetes Care closed in June across all four markets, bringing […]

Tandem Diabetes Care seeing early benefits of new pay-as-you-go model

By

Tandem Diabetes Care (Nasdaq: TNDM) says U.S. sales of its insulin pumps were boosted by a scaled pay-as-you-go reimbursement model that’s been rolling out this year. According to the San Diego–based company’s second-quarter report, released after market close yesterday, the alternative reimbursement structure, available through patients’ pharmacy benefits rather than medical benefits, eliminates upfront pump […]

BD, Ypsomed to develop new syringe for biologics

By

BD (NYSE: BDX) and Ypsomed recently announced they will expand their collaboration through the development of a 5.5 ml version of BD’s Neopak XtraFlow glass prefillable syringe. The new BD syringe is presently in development and will undergo comprehensive testing to ensure its compatibility with Ypsomed’s YpsoMate 5.5 autoinjector platform. Syringe samples for feasibility studies […]

Abbott launches universal FreeStyle Libre CGM app in U.S.

By

Abbott (NYSE: ABT) recently launched a smartphone app that works with both its FreeStyle Libre 2 and FreeStyle Libre 3 continuous glucose monitoring systems. “By listening to our customers, we developed a universal app with enhanced features to make living with diabetes easier,” Badia Boudaiffa, VP of North America commercial operations for Abbott’s diabetes care […]

BD to close infusion and syringe pumps facility in Israel

By

BD (NYSE: BDX) plans to close a facility in Caesarea, Israel, by the middle of the year.  Calcalist’s CTech out of Israel reported the news earlier today, saying that the closure affects 200 employees who will be let go. BD acquired the facility through its 2017 acquisition of Caesarea Medical Electronics, maker of infusion and syringe pumps and accessories for home […]